胰岛素信号的机制作为潜在的治疗方法在肠道疾病
Sara Jarmakiewicz-Czaja1, Aneta Sokal-Dembowska1, Katarzyna Ferenc2
1Institute of Health Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland.
Cells
|November 27, 2024
概括
通过了解IGF-1和GLP-1等胰岛素信号通路如何影响肠道炎症,可以进一步治疗炎症性肠病 (IBD). 针对这些途径,包括抗TL1A疗法,对IBD和其他肠道疾病有希望.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),是一个日益严重的全球健康挑战.
- 胃肠炎的发病率正在转变,在发展中国家增加,在发达国家减少,影响所有年龄组.
- 目前的研究正在探索新的治疗途径,重点关注胰岛素信号通路在胃肠道炎症中的作用.
研究的目的:
- 审查胰岛素样生长因子-1 (IGF-1),葡萄糖样-1 (GLP-1) 和瘤坏死因子样1A (TL1A) 对肠道微生物群和炎症的机制影响.
- 综合当前关于GLP-1,IGF-1和抗TL1A疗法如何影响肠道炎症和肠道微生物组的知识.
- 探索这些药物的潜力,以开发未来IBD和其他肠道疾病的治疗策略.
主要方法:
- 文献综述和现有研究的综合.
- 对研究GLP-1,IGF-1和TL1A对胃肠道炎症的影响的分析.
- 检查这些信号分子与肠道微生物群的组成和功能之间的相互作用的研究.
主要成果:
- 新兴证据表明,IGF-1,GLP-1和TL1A在调节肠道炎症和微生物平衡方面发挥着重要作用.
- 这些途径为IBD的治疗干预提供了潜在的目标.
- 了解它们与肠道微生物群的相互作用对于优化治疗疗效至关重要.
结论:
- 针对胰岛素信号通路,特别是IGF-1和GLP-1,以及TL1A调节,是IBD治疗的一个有希望的前沿.
- 对这些相互作用的机制进行进一步的研究可能会为一系列肠道疾病开启新的治疗策略.
- 本次审查强调了这些药物的潜力,以重塑炎症和微生物组相关的胃肠道疾病的管理.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Glucose Absorption Into the Small Intestine
31.3K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.3K
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
113


